Literature DB >> 22294984

Childhood-Adolescent Obesity in the Cardiorenal Syndrome: Lessons from Animal Models.

Melvin R Hayden, James R Sowers.   

Abstract

BACKGROUND/AIMS: Childhood-adolescent overweight and obesity have grown to pandemic proportions during the past decade. The onset of obesity in younger adults will likely be manifested as earlier onset of myocardial and renal end-organ disease in younger adults. For the first time, it is estimated that the current generation may not live to be as old as their parents. Thus, it is important to develop animal models of childhood obesity to understand fundamental pathological organ changes.
METHODS: In this regard, we utilize transmission electron microscopy evaluation to evaluate early remodeling changes of two adolescent rodent obesity models: the Zucker obese (fa/fa) rat and the db/db mouse models of obesity. We have concentrated on the initial ultrastructural remodeling (obese adipose tissue, skeletal muscle, and islet remodeling) and the associated changes in target end organs (including the myocardium and kidney) in young rodent models of obesity and insulin resistance, collectively manifesting as the cardiorenal metabolic syndrome (CRS).
RESULTS: Briefly, tissues revealed the following ultrastructural remodeling abnormalities: inflammation, hypertrophy, and early fibrosis in adipose tissue; loss of mitochondria in skeletal muscles, hyperplasia, fibrosis, and depletion of insulin-secretory granules in pancreatic islets; increased intramyocardial lipid accumulation, fibrosis, and mitochondrial deposition in the myocardium, and obesity-related glomerulopathy and tubulopathy in the kidney.
CONCLUSION: Based on the current knowledge and ultrastructural observations of organ pathology, we propose mechanisms whereby obesity appears to be the driving force behind the development of the CRS.
© 2011 S. Karger AG, Basel.

Entities:  

Keywords:  Adolescence; Childhood; Diabetes; Obesity; Rodent models; Ultrastructural remodeling

Year:  2011        PMID: 22294984      PMCID: PMC3263971          DOI: 10.1159/000327022

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  35 in total

Review 1.  Obesity and insulin resistance.

Authors:  B B Kahn; J S Flier
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Immigration and generational trends in body mass index and obesity in the United States: results of the National Latino and Asian American Survey, 2002-2003.

Authors:  Lisa M Bates; Dolores Acevedo-Garcia; Margarita Alegría; Nancy Krieger
Journal:  Am J Public Health       Date:  2007-11-29       Impact factor: 9.308

Review 3.  Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte.

Authors:  Melvin R Hayden; Adam Whaley-Connell; James R Sowers
Journal:  Am J Nephrol       Date:  2005 Nov-Dec       Impact factor: 3.754

4.  Youth type 2 diabetes: insulin resistance, beta-cell failure, or both?

Authors:  Neslihan Gungor; Fida Bacha; Rola Saad; Janine Janosky; Silva Arslanian
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

5.  Effects of Chronic Antagonism of Endocannabinoid-1 Receptors on Glucose Tolerance and Insulin Action in Skeletal Muscles of Lean and Obese Zucker Rats.

Authors:  Katherine A Lindborg; Stephan Jacob; Erik J Henriksen
Journal:  Cardiorenal Med       Date:  2011-01-17       Impact factor: 2.041

6.  Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002.

Authors:  Stephen Cook; Peggy Auinger; Chaoyang Li; Earl S Ford
Journal:  J Pediatr       Date:  2007-10-22       Impact factor: 4.406

7.  Declining beta-cell function relative to insulin sensitivity with increasing fasting glucose levels in the nondiabetic range in children.

Authors:  Hala Tfayli; SoJung Lee; Silva Arslanian
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 17.152

8.  Childhood predictors of young-onset type 2 diabetes.

Authors:  Paul W Franks; Robert L Hanson; William C Knowler; Carol Moffett; Gleebah Enos; Aniello M Infante; Jonathan Krakoff; Helen C Looker
Journal:  Diabetes       Date:  2007-08-24       Impact factor: 9.461

9.  National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.

Authors:  George Bakris; Joseph Vassalotti; Eberhard Ritz; Christoph Wanner; George Stergiou; Mark Molitch; Richard Nesto; George A Kaysen; James R Sowers
Journal:  Kidney Int       Date:  2010-08-18       Impact factor: 10.612

Review 10.  Pericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes.

Authors:  Melvin R Hayden; Ying Yang; Javad Habibi; Sarika V Bagree; James R Sowers
Journal:  Oxid Med Cell Longev       Date:  2010-09-01       Impact factor: 6.543

View more
  4 in total

Review 1.  The Mighty Mitochondria Are Unifying Organelles and Metabolic Hubs in Multiple Organs of Obesity, Insulin Resistance, Metabolic Syndrome, and Type 2 Diabetes: An Observational Ultrastructure Study.

Authors:  Melvin R Hayden
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 2.  Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human Pathology.

Authors:  Tim D Hewitson; Stephen G Holt; Edward R Smith
Journal:  Front Immunol       Date:  2015-09-17       Impact factor: 7.561

3.  Myocardial Integrated Backscatter in Obese Adolescents: Associations with Measures of Adiposity and Left Ventricular Deformation.

Authors:  Lijian Xie; Elim Man; Pik-To Cheung; Yiu-Fai Cheung
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

Review 4.  An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of β-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms.

Authors:  Melvin R Hayden
Journal:  Cells       Date:  2020-11-13       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.